Sartorius Stedim Biotech SA

Sartorius Stedim Biotech SA

247.00
USD
+1.15
(+0.47%)
3.80EPS
64.48P/E
23.71BMarket Cap
Feb 23Next Earn

Total Valuation

USD

As of September 30, 2026, Sartorius Stedim Biotech carries a market capitalization of 23.71B, placing it among publicly traded companies globally. Its enterprise value stands at 26.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap23.71B
Enterprise Value26.11B

Important Dates

Sartorius Stedim Biotech's next confirmed earnings release is scheduled for February 23, 2027.

Earnings Date2/23/2027

Share Statistics

As of September 30, 2026, Sartorius Stedim Biotech has 97.29M shares outstanding.

Shares Outstanding97.29M

Valuation Ratios

As of September 30, 2026, Sartorius Stedim Biotech trades at a trailing price-to-earnings ratio of 64.48. The price-to-sales ratio is 6.82, and the price-to-book ratio stands at 4.78.

PE Ratio64.48
PS Ratio6.82
PB Ratio4.78
P/TBV Ratio34,872.44
P/FCF Ratio52.86
P/OCF Ratio28.07

Enterprise Valuation

As of September 30, 2026, Sartorius Stedim Biotech trades at an EV/EBITDA multiple of 25.17 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.52 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 39.12 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Sartorius Stedim Biotech trades at an EV/FCF ratio of 49.06, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 26.11B versus a market cap of 23.71B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales7.52
EV / EBITDA25.17
EV / EBIT39.12
EV / FCF49.06

Financial Position

As of September 30, 2026, Sartorius Stedim Biotech maintains a current ratio of 1.22, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 52.62, indicating elevated leverage, while an interest coverage ratio of 8.82 demonstrates adequate ability to service its debt obligations.

Current Ratio1.22
Quick Ratio0.18
Debt / Equity52.62
Debt / EBITDA2.53
Interest Coverage8.82

Financial Efficiency

USD

These figures cover the twelve months ended September 30, 2026. The company generates approximately 338,032.95 in revenue per employee across its workforce of 10,265.00, a quick read on workforce productivity versus industry peers.

Revenue Per Employee338,032.95
Employee Count10,265.00

Taxes

USD

Over the twelve months ended September 30, 2026, Sartorius Stedim Biotech recorded 145.42M in income tax expense. That works out to an effective tax rate of 28.27, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 514.45M, leaving 367.11M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax145.42M
Effective Tax Rate28.27

Stock Price Statistics

USD

As of the close on November 16, 2026, Sartorius Stedim Biotech's stock has gained approximately 10.02% over the past 52 weeks. The 50-day moving average sits at 217.46, while the 200-day moving average is 214.87.

52-Week Price Change10.02%
50-Day Moving Average217.46
200-Day Moving Average214.87

Income Statement

USD

Over the twelve months ended September 30, 2026, Sartorius Stedim Biotech generated 3.47B in revenue and converted that into 367.11M in net income, yielding earnings per share of 3.80. EBITDA reached 1.04B, while operating income came in at 667.35M.

Revenue3.47B
Gross Profit1.55B
Operating Income667.35M
Pretax Income514.45M
Net Income367.11M
EBITDA1.04B
EBIT667.35M
Earnings Per Share (EPS)3.80

Balance Sheet

USD

As of September 30, 2026, Sartorius Stedim Biotech holds 239.60M in cash and equivalents against 2.62B in total debt, resulting in a net debt position of 2.23B. Total book value stands at 4.96B, with working capital of 285.39M providing operational flexibility.

Cash & Cash Equivalents239.60M
Total Debt2.62B
Net Debt2.23B
Equity (Book Value)4.96B
Book Value Per Share51.00
Working Capital285.39M

Cash Flow

USD

Sartorius Stedim Biotech produced 843.36M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -395.56M in capital expenditures, free cash flow totaled 447.81M - equivalent to 4.61 per share.

Operating Cash Flow843.36M
Capital Expenditures-395.56M
Free Cash Flow447.81M
FCF Per Share4.61

Margins

Over the twelve months ended September 30, 2026, Sartorius Stedim Biotech posted a gross margin of 44.55, reflecting its pricing power and cost economics. The operating margin of 19.23 and net profit margin of 10.58 provide insight into operational efficiency.

Gross Margin44.55
Operating Margin19.23
Pretax Margin14.83
Profit Margin10.58
EBITDA Margin29.89

Dividends & Yields

Over the twelve months ended September 30, 2026, Sartorius Stedim Biotech paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.89, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 2.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sartorius Stedim Biotech shareholders.

Shareholder Yield2.50
FCF Yield1.89

Stock Splits

Sartorius Stedim Biotech's most recent stock split took place on May 6, 2016 with a 1:6 split ratio.

Last Split Date5/6/2016
Split Ratio1:6

Scores

As of September 30, 2026, Sartorius Stedim Biotech has an Altman Z-Score of 6.01, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.01